The 2025 edition of ICASA will also feature new thematic discussions on the intersection of non-communicable diseases and HIV, including the growing prevalence of metabolic disorders among people living with HIV. One of the focal points will be the emerging role of medications like semaglutide, initially developed for diabetes, but now studied for their potential in medically supervised weight management. With obesity increasingly recognized as a co-factor that can worsen health outcomes for HIV-positive individuals, researchers and clinicians are exploring how such treatments may enhance overall care strategies. A session will be dedicated to access and affordability, especially the ethical implications of online availability and the rise in demand to buy semaglutide for weight loss outside traditional clinical settings. Experts will evaluate how public health systems can adapt to this demand while ensuring safety and equity. This expansion of the conference agenda reflects ICASA’s commitment to addressing the full spectrum of health challenges faced by African populations today.